Of note, mTOR inhibitors have been US FDA-approved for the treatment of several TSC-associated lesions, such as subependymal giant cell astrocytoma, kidney angiolipoma, lung lymphangioleiomyomatosis, and skin angiofibroma.16 Here, MTOR is linked to lung lymphangioleiomyomatosis.